Keywords: Amylin, Takeda, Pramlintidfe, Davalintide, Research

Amylin and partner Takeda move obesity drug candidate into Ph III

Article | 25 February 2010

USA-based Amylin Pharmaceuticals and Japan’s largest drugmaker, Takeda Pharmaceutical says they have selected the combination treatment of pramlintide, an ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Amylin

Go to company listing

Related Drugs

Amino Acids

Injection

Physostigmine Salicylate

Go to drug listing